Document is current
Any future updates will be listed below
-
Authors
Koch, Mathilde Rønne
Buhl Rasmussen, Anna Sofie https://orcid.org/0000-0002-4997-2914
Als-Nielsen, Bodil
Duarte, Ximo https://orcid.org/0000-0001-5332-0284
Escherich, Gabriele
Heyman, Mats
Lepik, Kristi
Malmros, Johan
Nersting, Jacob https://orcid.org/0000-0001-9144-7972
Johannsdottir, Inga
Niinimäki, Riitta
Petersen, Malene Johanne https://orcid.org/0000-0002-0531-8531
Segers, Heidi https://orcid.org/0000-0002-3604-7850
van der Sluis, Inge Margriet
Thastrup, Maria https://orcid.org/0000-0001-9950-5911
Vaitkeviciene, Goda
Schmiegelow, Kjeld https://orcid.org/0000-0002-0829-4993
Toksvang, Linea Natalie https://orcid.org/0000-0002-9871-7637
-
Funding
Funding for this research was provided by:
National Hospital
- License Information
-
More Information
Article History
Received: 7 March 2025
Accepted: 16 June 2025
First Online: 16 July 2025
Declarations
:
: A liquid formulation of 6-thioguanine (6TG) is provided by Novalab to the TEAM trial ( no NCT04307576), but the patients receiving 6TG are not included in this study.
: This study is part of the A2G Maintenance Therapy sub-study to the ALLTogether1 study (EU CT nr 2022-501050-11-01). Oral and written consent was obtained from parents/caregivers and patients when appropriate. The study was approved on October 28th, 2020, in the European voluntary harmonization process (VHP1557/SA1[VHP2019111/SA1], current amendment accepted November 12th, 2021; VHP1557/SA3[VHP2019111/SA3]), followed by individual approval in participating countries by ethics committees.
